Dr Fatima   Valdes Mora
Conjoint Senior Lecturer

Dr Fatima Valdes Mora

BSc in Biochemistry, (2000-2004), Autonomous University of Madrid (Spain)

PhD in Biochemistry, Molecular Biology and Biomedicine (09/2004-12/2008), Autonomous University of Madrid (Spain)

medicine-health
Sch Women's&Children's Health

I am a mid-early career researcher arising as an authority in cancer epigenetics, single-cell transcriptomics, and epigenomics. During my career, I have made seminal discoveries in the field of histone variants and cancer epigenetics (Genome Research 2012, Nature Comms 2017, and iScience 2019) where I demonstrated an oncogenic role for acetylation of the histone variant H2A.Z. In the last 5 years, I have also focused on cutting-edge technology implementation, single-cell RNAseq, for the understanding of tumour biology transcriptionally (Cell Reports 2021) and more recently epigenetically, single-cell ATAC-seq. One of the current main foci of my group is the understanding of the epigenetic causes of childhood cancer. https://www.ccia.org.au/about-the-institute/our-research/personalised-medicine/cancer-epigenetic-biology-and-therapeutics

I obtained my PhD in Molecular Biology, Biochemistry, and Biomedicine from CSIC (Autonoma University of Madrid, Spain) in December 2008. I completed my postdoctoral research at Prof Susan Clark’s lab (Garvan Institute, Sydney Australia) in 2013 and obtained a Group Leader appointment at Garvan in 2014 to lead the Histone Variant Group. I have recently joined the Children’s Cancer Institute as Team Leader of the “Cancer Epigenetic Biology and Therapeutics” lab. From 2014, I hold a conjoint Senior Lecturer position at UNSW Sydney that have allowed me to supervise multiple Masters, Honours, and PhD students

I have published 26 peer-reviewed papers since 2004 (15 as corresponding/first author), from which 15 have been published in the last 5 years. During my postdoctoral stage, I have attracted > €2.7 M of competitive funding (as fellowships and research grants) from both public and private Australian funding bodies, including, the highly competitive NHMRC project grants (current success rate is <10%), Cancer Institute NSW, Prostate Cancer Foundation of Australia (PCFA), National Breast Cancer Foundation (NBCF) and Cure Cancer. I currently hold a CINSW Career Development Fellowship which is allowing her to establish my own research niche in epigenomics and cancer.

I have a passion for the development and implementation of novel technology that has allowed her to develop a multidisciplinary profile. I have a strong profile in molecular biology, epigenetics, single-cell transcriptomics, next-generation sequencing and bioinformatics interpretation of genome-wide data. I perform extremely well as a hinge joint between bioinformatics and biology, interpreting and integrating sequencing data into meaningful biological outputs.

Publications

  • Book Chapters | 2018
    Dr Fatima Valdes Mora
    Valdés-Mora F; Stirzaker C, 2018, 'Epigenetic Alterations in Primary Prostate Cancer', in Molecular Pathology Library, Springer International Publishing, pp. 193 - 211, http://dx.doi.org/10.1007/978-3-319-64096-9_13
    Book Chapters | 2016
    Dr Fatima Valdes Mora
    Valdes-Mora F; Lee HJ, 2016, 'Single-Cell Genomics and Epigenomics', in Tseng FG; Santra TS (ed.), Essentials of Single-Cell Analysis Concepts, Applications and Future Prospects, edn. Series in BioEngineering, SPRINGER-VERLAG BERLIN, pp. 257 - 301, http://dx.doi.org/10.1007/978-3-662-49118-8_10
  • Journal articles | 2021
    Dr Fatima Valdes Mora
    Valdés-Mora F; Salomon R; Gloss BS; Law AMK; Venhuizen J; Castillo L; Murphy KJ; Magenau A; Papanicolaou M; Rodriguez de la Fuente L; Roden DL; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Sikta N; Oakes SR; Cox TR; O'Donoghue SI; Timpson P; Ormandy CJ; Gallego-Ortega D, 2021, 'Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype', Cell Reports, vol. 35, http://dx.doi.org/10.1016/j.celrep.2021.108945
    Journal articles | 2020
    Dr Fatima Valdes Mora
    Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, vol. 11, http://dx.doi.org/10.1038/s41467-019-14098-x
    Journal articles | 2020
    Dr Fatima Valdes Mora
    Law AMK; Valdes-Mora F; Gallego-Ortega D, 2020, 'Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer', Cells, vol. 9, http://dx.doi.org/10.3390/cells9030561
    Journal articles | 2020
    Dr Fatima Valdes Mora
    Salazar-Roa M; Trakala M; Álvarez-Fernández M; Valdés-Mora F; Zhong C; Muñoz J; Yu Y; Peters TJ; Graña-Castro O; Serrano R; Zapatero-Solana E; Abad M; Bueno MJ; de Cedrón MG; Fernández-Piqueras J; Serrano M; Blasco MA; Wang DZ; Clark SJ; Izpisua-Belmonte JC; Ortega S; Malumbres M, 2020, 'Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells', EMBO Journal, vol. 39, http://dx.doi.org/10.15252/embj.2019104324
    Journal articles | 2020
    Dr Fatima Valdes Mora
    Khoury A; Achinger-Kawecka J; Bert SA; Smith GC; French HJ; Luu PL; Peters TJ; Du Q; Parry AJ; Valdes-Mora F; Taberlay PC; Stirzaker C; Statham AL; Clark SJ, 2020, 'Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains', Nature Communications, vol. 11, http://dx.doi.org/10.1038/s41467-019-13753-7
    Journal articles | 2020
    Dr Fatima Valdes Mora
    Salomon R; Martelotto L; Valdes-Mora F; Gallego-Ortega D, 2020, 'Genomic Cytometry and New Modalities for Deep Single-Cell Interrogation', Cytometry Part A, vol. 97, pp. 1007 - 1016, http://dx.doi.org/10.1002/cyto.a.24209
    Journal articles | 2019
    Dr Fatima Valdes Mora
    Valdes-Mora F; Salomon R; Gloss B; Law AMK; Murphy K; Roden DL; Castillo L; Colino-Sanguino Y; Farbehi N; Conway J; Timpson P; Ormandy CJ; Gallego-Ortega D, 2019, 'Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p022
    Journal articles | 2019
    Dr Fatima Valdes Mora
    Salomon R; Kaczorowski D; Valdes-Mora F; Nordon RE; Neild A; Farbehi N; Bartonicek N; Gallego-Ortega D, 2019, 'Droplet-based single cell RNAseq tools: A practical guide', Lab on a Chip, vol. 19, pp. 1706 - 1727, http://dx.doi.org/10.1039/c8lc01239c
    Journal articles | 2019
    Dr Fatima Valdes Mora
    Colino-Sanguino Y; Cornett EM; Moulder D; Smith GC; Hrit J; Cordeiro-Spinetti E; Vaughan RM; Krajewski K; Rothbart SB; Clark SJ; Valdés-Mora F, 2019, 'A Read/Write Mechanism Connects p300 Bromodomain Function to H2A.Z Acetylation', iScience, vol. 21, pp. 773 - 788, http://dx.doi.org/10.1016/j.isci.2019.10.053
    Journal articles | 2019
    Dr Fatima Valdes Mora
    Valdes-Mora F; Salomon R; Gloss B; Law AMK; Castillo L; Murphy K; Venhuizen J; Magenau A; Papanicolau M; de la Fuente LR; Roden D; Colino-Sanguino Y; Kikhtyak Z; Farbehi N; Conway JRW; Oakes S; Sikta N; O’Donoghue S; Cox T; Timpson P; Ormandy C; Gallego-Ortega D, 2019, 'Single cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype', , http://dx.doi.org/10.1101/624890
    Journal articles | 2018
    Dr Fatima Valdes Mora
    Valdes-Mora F; Handler K; Law AMK; Salomon R; Oakes SR; Ormandy CJ; Gallego-Ortega D, 2018, 'Single-cell transcriptomics in cancer immunobiology: The future of precision oncology', Frontiers in Immunology, vol. 9, http://dx.doi.org/10.3389/fimmu.2018.02582
    Journal articles | 2017
    Dr Fatima Valdes Mora
    Stirzaker C; Song JZ; Ng W; Du Q; Armstrong NJ; Locke WJ; Statham AL; French H; Pidsley R; Valdes-Mora F; Zotenko E; Clark SJ, 2017, 'Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer', Oncogene, vol. 36, pp. 1328 - 1338, http://dx.doi.org/10.1038/onc.2016.297
    Journal articles | 2017
    Dr Fatima Valdes Mora
    Valdés-Mora F; Locke WJ; Bandrés E; Gallego-Ortega D; Cejas P; García-Cabezas MA; Colino-Sanguino Y; Feliú J; del Pulgar TG; Lacal JC, 2017, 'Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer', Oncotarget, vol. 8, pp. 26755 - 26770, http://dx.doi.org/10.18632/oncotarget.15815
    Journal articles | 2017
    Dr Fatima Valdes Mora
    Valdés-Mora F; Gould CM; Colino-Sanguino Y; Qu W; Song JZ; Taylor KM; Buske FA; Statham AL; Nair SS; Armstrong NJ; Kench JG; Lee KML; Horvath LG; Qiu M; Ilinykh A; Yeo-Teh NS; Gallego-Ortega D; Stirzaker C; Clark SJ, 2017, 'Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer', Nature Communications, vol. 8, http://dx.doi.org/10.1038/s41467-017-01393-8
    Journal articles | 2016
    Dr Fatima Valdes Mora
    Colino-Sanguino Y; Clark SJ; Valdes-Mora F, 2016, 'H2A.Z acetylation and transcription: Ready, steady, go!', Epigenomics, vol. 8, pp. 583 - 586, http://dx.doi.org/10.2217/epi-2016-0016
    Journal articles | 2015
    Dr Fatima Valdes Mora
    Valdés-Mora F; Clark SJ, 2015, 'Prostate cancer epigenetic biomarkers: next-generation technologies', Oncogene, vol. 34, pp. 1609 - 1618, http://dx.doi.org/10.1038/onc.2014.111
    Journal articles | 2015
    Dr Fatima Valdes Mora
    Gallego-Ortega D; Ledger A; Roden DL; Law AMK; Magenau A; Kikhtyak Z; Cho C; Allerdice SL; Lee HJ; Valdes-Mora F; Herrmann D; Salomon R; Young AIJ; Lee BY; Sergio CM; Kaplan W; Piggin C; Conway JRW; Rabinovich B; Millar EKA; Oakes SR; Chtanova T; Swarbrick A; Naylor MJ; O’Toole S; Green AR; Timpson P; Gee JMW; Ellis IO; Clark SJ; Ormandy CJ, 2015, 'ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells', PLoS Biology, vol. 13, http://dx.doi.org/10.1371/journal.pbio.1002330
    Journal articles | 2013
    Dr Fatima Valdes Mora
    Stone A; Valdes-Mora F; Clark SJ, 2013, 'Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer', Epigenomics, vol. 5, pp. 595 - 598, http://dx.doi.org/10.2217/epi.13.70
    Journal articles | 2013
    Dr Fatima Valdes Mora
    Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, vol. 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012
    Journal articles | 2012
    Dr Fatima Valdes Mora
    Stone A; Valdes-Mora F; Gee JM; Farrow L; Mcclelland RS; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Robert i nicholson RI, 2012, 'Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer', PLoS One, vol. 7, pp. e40466, http://dx.doi.org/10.1371/journal.pone.0040466
    Journal articles | 2012
    Dr Fatima Valdes Mora
    Valdes-Mora F; Song JZ; Statham AL; Strbenac D; Robinson MD; Nair SS; Patterson K; Tremethick DJ; Stirzaker C; Clark SJ, 2012, 'Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer', Genome Research, vol. 22, pp. 307 - 321, http://dx.doi.org/10.1101/gr.118919.110
    Journal articles | 2012
    Dr Fatima Valdes Mora
    Kalyuga M; Gallego-Ortega D; Lee H; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Rosalind launchbury R; Statham A; Armstrong NJ; Alles MC; Adelaide young A; Egger A; Au W; Piggin CL; Evans C; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Robert i nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer', PLoS Biology, vol. 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461
    Journal articles | 2011
    Dr Fatima Valdes Mora
    Gallego-Ortega D; Gómez del Pulgar T; Valdés-Mora F; Cebrián A; Lacal JC, 2011, 'Involvement of human choline kinase alpha and beta in carcinogenesis: A different role in lipid metabolism and biological functions', Advances in Enzyme Regulation, vol. 51, pp. 183 - 194, http://dx.doi.org/10.1016/j.advenzreg.2010.09.010
    Journal articles | 2011
    Dr Fatima Valdes Mora
    Lee HJ; Hinshelwood R; Bouras T; Gallego-Ortega D; Valdes-Mora F; Blazek K; Visvader JE; Clark SJ; Ormandy CJ, 2011, 'Lineage specific methylation of the Elf5 promoter in mammary epithelial cells', Stem Cells, vol. 29, pp. 1611 - 1619, http://dx.doi.org/10.1002/stem.706
    Journal articles | 2011
    Dr Fatima Valdes Mora
    Valdés-Mora F; Gómez DPT; Lacal JC, 2011, 'CDC42 (cell division cycle 42 (GTP binding protein, 25kDa))', Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://dx.doi.org/10.4267/2042/44606
    Journal articles | 2011
    Dr Fatima Valdes Mora
    Valdés-Mora F; Gómez DPT; Lacal JC, 2011, 'TWIST1 (twist homolog 1 (Drosophila))', Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://dx.doi.org/10.4267/2042/44846
    Journal articles | 2009
    Dr Fatima Valdes Mora
    Gallego-Ortega D; de Molina AR; Ramos MA; Valdes-Mora F; Barderas MG; Sarmentero-Estrada J; Lacal JC, 2009, 'Differential role of human choline kinase α and β enzymes in lipid metabolism: Implications in cancer onset and treatment', PLoS ONE, vol. 4, http://dx.doi.org/10.1371/journal.pone.0007819
    Journal articles | 2009
    Dr Fatima Valdes Mora
    Valdés-Mora F; Gómez Del Pulgar T; Bandrés E; Cejas P; Ramírez De Molina A; Pérez-Palacios R; Gallego-Ortega D; García-Cabezas MA; Casado E; Larrauri J; Nistal M; González-Barón M; García-Foncillas J; Lacal JC, 2009, 'TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer', Annals of Surgical Oncology, vol. 16, pp. 78 - 87, http://dx.doi.org/10.1245/s10434-008-0166-x
    Journal articles | 2008
    Dr Fatima Valdes Mora
    Gómez Del Pulgar T; Valdés-Mora F; Bandrés E; Pérez-Palacios R; Espina C; Cejas P; García-Cabezas MA; Nistal M; Casado E; González-Barón M; García-Foncillas J; Lacal JC, 2008, 'Cdc42 highly expressed in colorectal adecarcinoma and downregulates ID4 through an epigenetic mechanism', International Journal of Oncology, vol. 33, pp. 185 - 193
    Journal articles | 2008
    Dr Fatima Valdes Mora
    Gallego-Ortega D; de Molina AR; Ramos MA; Valdes-Mora F; Sarmentero-Estrada J; Lacal JC, 2008, 'Differential role of choline kinase alpha and beta isoforms in human carcinogenesis', European Journal of Cancer Supplements, vol. 6, pp. 26 - 26, http://dx.doi.org/10.1016/s1359-6349(08)71275-8
    Journal articles | 2007
    Dr Fatima Valdes Mora
    Gómez del Pulgar T; Bandrés E; Espina C; Valdés-Mora F; Pérez-Palacios R; García-Amigot F; García-Foncillas J; Lacal JC, 2007, 'Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer', International Journal of Biochemistry and Cell Biology, vol. 39, pp. 2289 - 2302, http://dx.doi.org/10.1016/j.biocel.2007.06.014
    Journal articles |
    Dr Fatima Valdes Mora
    Salazar-Roa M; Trakala M; Álvarez-Fernández M; Valdés-Mora F; Zhong C; Muñoz J; Yu Y; Peters TJ; Graña O; Serrano R; Zapatero-Solana E; Abad M; Bueno MJ; de Cedrón MG; Fernández-Piqueras J; Serrano M; Blasco MA; Wang D-Z; Clark SJ; Izpisua-Belmonte JC; Ortega S; Malumbres M, 'A novel microRNA-based strategy to expand the differentiation potency of stem cells', , http://dx.doi.org/10.1101/826446
  • Conference Abstracts | 2015
    Dr Fatima Valdes Mora
    Gallego-Ortega D; Ledger A; Roden D; Cho C; Allerdice SL; Lee HJ; Valdes-Mora F; Lee B; Kaplan W; Salomon R; Piggin C; Rabinovich B; Millar E; Chtanova T; Swarbrick A; Clark S; Ormandy C, 2015, 'The ETS transcription factor ELF5 drives metastasis via angiogenesis and recruitment of Gr-1+ CD11b+ myeloid derived suppressor cells in luminal breast cancer', in Clinical and Experimental Metastasis, Springer Verlag (Germany), Vol. 32, pp. 203 - 203, presented at MRS 15th International biennial congress of the metastasis research society, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351601900067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
    Conference Papers | 2014
    Dr Fatima Valdes Mora
    Ortega DG; Ledger A; Roden D; Cho C; Allerdice S; Lee H; Valdes-Mora F; Salomon R; Oakes S; Ormandy C, 2014, 'THE ETS TRANSCRIPTION FACTOR ELF5 IS A KEY DETERMINANT OF THE LETHAL PHENOTYPE IN LUMINAL BREAST CANCER, DRIVING THE ACQUISITION OF ANTIESTROGEN RESISTANCE AND METASTATIC ACTIVITY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 16 - 17, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2008
    Dr Fatima Valdes Mora
    Valdes-Mora F; Gomez del Pulgar T; Bandres E; Cejas P; Ramirez de Molina A; Perez-Palacios R; Gallego-Ortega D; Angel Garcia-Cabezas M; Garcia-Foncillas J; Carlos Lacal J, 2008, 'TWIST1 overexpression is associated with nodal invasion and male gender in primary colorectal cancer', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Lyon, FRANCE, pp. 154 - 154, presented at 20th Meeting of the European-Association-for-Cancer-Research, Lyon, FRANCE, 05 July 2008 - 08 July 2008, http://dx.doi.org/10.1016/S1359-6349(08)71767-1

Awards

Grants

2021-2023. Co-Investigator 2. Investigator initiated Research Scheme. National Breast Cancer Foundation. (3 years, $393,078). Ranked Top 1 nationally.

2021-2022. CIA. The Cure Starts Now. (1 year, $150, 379)

2020-2021. Co-Investigator Seed Funding Award UNSW Cellular Genomics Futures Institute. (1 year, $100,000). CIA Dr Fatemeh Vafaee.

2020. Co-Investigator 3R project UNSW. (1 year, $65,000). CIA Dr David Gallego Ortega

2019-2021. Cancer Institute NSW Career Development Fellowship (CDF181218, 3 years $ 600,000). Sole CIA

2018-2020. Co-Investigator B in NHMRC project grant (APP1144574, 3 years $ 859,350). CIA Prof Susan Clark.

2014-2016. Co-Investigator B in NHMRC project grant (APP1063560, 3 years $591,599). CIA Prof Susan Clark.

2011-2013. Co-Investigator of Prostate Cancer Foundation of Australia Project Grant. (PG4310. 3 years, $ 375K). CIA Prof Susan Clark.

2013-2018. National Breast Cancer Foundation/ Cure Cancer Australia Foundation Postdoctoral Training Fellowship (PF-13-11. 4 years excluding career disruption, $400K). Sole CIA

Media